Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Eryaknen, Eryfluid, Erystad, Erythrocin, Erythromycin, Meromycin; Belgium: Acneryne, Aknemycin, Erythrocine, Erythroforte, Inderm, Stimycine; Bulgaria: Acnerin, Erythran; Cyprus: Ermyced, Ermycin, Erythran, Porphyrocin, Stiemycin; Czech Republic: Aknefug-EL, Aknemycin, Eryfluid; Denmark: Abboticin, Erycin, Escumycin, Hexabotin; Estonia: Aknefug-EL; Finland: Abboticin, Ermysin; France: Abboticine, Egery, Ery, Eryacne, Eryfluid, Erithrocine, Erhytrogel, Erythromycine, Stimycine; Germany: Akne Cordes, Aknederm Ery Gel, Aknefug-EL, Aknemago, Aknemycin, Ery, Eryaknen, Erybeta TS, Erycinum, Erydermec, Eryfluid, EryHEXAL, Erykanen, Erysec, Erythro-CT, Erythrocin, Erythromycin, Erytrotil, Hydrodermed Ery, Inderm, Infectomycin, Paediathrocin forte, Sanasepton; Greece: Acne Hermal, Dankit, Eritromicina, Erycinum, Erygel, Erythrocin, Erythromycin, Erythropen; Hungary: Aknefug-EL, Aknemycin, Erythromycin, Erythrotrop, Meromycin; Ireland: Erymax, Erythrocin, Erythromycin, Erythroped, Primacine, Stiemycin; Italy: Eritro E, Eritro L, Eritro S, Eritrocina, Eritromicina, Eryacne, Lauromicina; Latvia: Aknefug-EL, Erythromycin, Porphyrocin; Lithuania: Aknefug-EL, Erythromycin; Luxembourg: Acneryne, Akne-Mycin, Aknemycin, Ery, Eryderm, Eryfluid, EryHEXAL, Erythro, Erythrocine, Erythromycin, Erythromycine, Ilosone, Inderm, Macromycine, Monomycin, Stiemycin; Malta: Erythromycin, Primacine, Stiemycin; Netherlands: Erytrolyve; Poland: Acnecin, Aknemycin, Davercin, Erythromycinum; Portugal: Akne-Mycin, Clinac, Eritrazon, Eritrocel, Eritrocina, Eryfluid; Romania: Eritromagis, Eritromicina, Eryfluid; Slovakia: Aknefug-EL, Aknemycin, Eryfluid, Erythromycin, Inderm; Slovenia: Eritromicin; Spain: Bronsema, Deripil, Eridosis, Eritrogobens, Eritromicina, Eritroveinte, Euskin, Lagarmicin, Loderm, Pantomicina; Sweden: Abboticin, Ery-Max; UK: Eryacne, Erymax, Erythrocin, Erythromycin.

North America

Canada: AK Mycin Oph ONT, Diomycin, Erybid, Eryc, Erysol, Erythro, Erythrocin, Erythromycin; USA: Akne-Mycin, E-Glades, E.E.S., Ery-Tab, Eryc, Erygel, EryPed, Erythra-Derm, Erythro-Statin, Erythrocin, Erythromycin, PCE, Pediamycin.

Latin America

Argentina: Algiderm, Atlamicin, Clarex, Eri, Erigrand, Erisine, Erisol, Erit Bioquin, Eritrofarm, Eritromed, Eritromicina, Eritrovis, Eryacne, Etisux, Iloticina, Kitacne, Oftalmolets, Pantomicina, Pentoclave, Toperit, Trixne, Wemid; Brazil: Eribiotic, Eritrex, Eryacnen, Ilosone, Kanazima, Pantomicina, Stiemycin, Valmicin-Eritromicina; Mexico: Apo-Trina, Bestocin, Biotril, Eribec, Eriber, Erisuspen, Eritrolat, Eritromicina, Eritrosol, Eritrovier, Eritrowel, Eryacnen, Eryderm, Erylar, Iliocin, Ilosin, Iqfamicina, Lantrom, Latotryd, Lauricin, Lauritran, Optomicin, Pantomicina, Pertrosom, Procephal, Promicin, Quimolauril, Sansascne, Stiemycin, T-Stat, Witromin.


Japan: Elislit, Erythrocin, Erythromycin.

Drug combinations

Erythromycin and Benzoyl Peroxide

Erythromycin and Bromhexine

Erythromycin and Colismethate

Erythromycin and Ethanol

Erythromycin and Isotretinoin

Erythromycin and Sulfisoxazole

Erythromycin and Tretinoin

Erythromycin and Zinc


Erythromycin: C~37~H~67~NO~13~. Mw: 733.93. (1)(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. CAS-114-07-8.

Pharmacologic Category

Antibacterials; Macrolides; Erythromycins. EENT Preparations; Antibacterials. Skin and Mucous Membrane Agents; Antibacterials. Acne Product. (ATC-Code: D10AF02; J01FA01; S01AA17).

Mechanism of action

A macrolide antibiotic. Inhibits RNA-dependent protein synthesis at the chain elongation step. Binds to the 50S ribosomal subunit resulting in blockage of transpeptidation.

Therapeutic use

Treatment of susceptible bacterial infections including S. pyogenes, some S. pneumoniae, some S. aureus, M. pneumoniae, Legionella pneumophila, diphtheria, pertussis, Chlamydia, erythrasma, N. gonorrhoeae, E. histolytica, syphilis and nongonococcal urethritis, and Campylobacter gastroenteritis. Used in conjunction with neomycin for decontaminating the bowel. Treatment of superficial eye infections involving conjunctiva or cornea. Neonatal ophthalmia. Treatment of acne vulgaris.

Pregnancy and lactiation implications

No adequate, well-controlled studies completed in pregnant women. The estolate form of erythromycin should not be used in pregnancy due to a potential increased risk for hepatic toxicity. Caution if administered to breast-feeding women.

Unlabeled use

Treatment of gastroparesis, chancroid. Preoperative gut sterilization.


Hypersensitivity to erythromycin or any component of the formulation. Concomitant use with pimozide or cisapride.

Warnings and precautions

Macrolides associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes (use with caution in risk of prolonged cardiac repolarization). Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Use with caution in pre-existing liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, observed. Associated with aggravation of weakness associated with myasthenia gravis. High potential for drug interactions exists (use caution with any agents with substantial metabolism through the CYP3A4 pathway). Use of erythromycin associated with infantile hypertrophic pyloric stenosis. The elderly may be at increased risk of adverse events, including hearing loss and/or torsade de pointes when dosage ≥4 g/day, particularly if concurrent renal/hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart